6.心脏-循环系统药物 6.1.强心剂迄今,对强心甙和利尿剂难治性心机能不全,既不能通过β-肾上腺素能阻滞剂,也不能通过磷酸二酯酶(PDE)阻滞剂,获得重大的治疗进展。氨力农不能满足人们的厚望。米力农或依诺昔酮(参看第18部分)是否具有明显的优点,尚不能作出最后评价。目前人们假设,也许通过只选择性地影响同功酶Ⅲ,并使收缩蛋白对钙离子敏感性升高的PDE阻滞剂,可使疗效获得改善,例如使 6. Cardiac-Circulatory System Medications 6.1. Cardiotonics Up to now, refractory cardiac dysfunction to both cardiac glycosides and diuretics has failed either through β-adrenergic blockers or through phosphodiesterase (PDE) blockade Agent, access to major treatment progress. Ammonia can not satisfy people’s expectations. Milrinone or enoximone (see section 18) has obvious advantages, but can not make a final assessment. It has been hypothesized that the efficacy may be improved by perhaps PDE blockers that selectively affect isoenzyme III and increase the sensitivity of contractile proteins to calcium ions,